Developing EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia

Wednesday 28 May 2014

Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED).
Learn more on Edimer website.

Resources directory
on rare skin diseases

Care lookup

Looking for a specialist or a patients association?

Check our network map.

Follow us

Fondation René Touraine